Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1700141

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bowel Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve genomics testing for bowel cancer patients.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	20972
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>A National Health Service testing programme is helping to diagnose thousands of people with a genetic condition, Lynch Syndrome, that increases the chance of developing certain cancers including bowel cancer. The national programme ensures all people diagnosed with bowel cancer are offered genomic testing, with a diagnosis for Lynch Syndrome not only helping to guide more personalised cancer treatment but enabling their families and relatives to be offered testing too. Relatives who receive a diagnosis of Lynch Syndrome can be referred to genetic services to discuss regular testing options to help catch any cancers as early as possible, as well as to consider preventive options such as taking aspirin or undergoing risk-reducing surgery.</p><p>Genomic testing in the NHS in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (NGTD) which outlines the full range of genomic testing offered by the NHS in England including tests for 3,200 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used, including testing for bowel cancer patients.</p><p>The NHS GMS cancer genomic testing strategy has facilitated a move to a consolidated laboratory network through the seven NHS GLHs delivering more extensive panel testing using cutting edge high throughput Next Generation Sequencing (NGS) technology. For patients, including those with bowel cancer, this technology enables testing for a larger number of genetic variations to give a more precise diagnosis, identify biomarkers to target treatment and opportunities to access innovative medicines, and can support enrolment into molecularly stratified clinical trials.</p><p>Testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional (for example, their general practitioner or other healthcare professional if they are already being seen in a relevant service) whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS clinical genomics service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.</p><p>The 17 NHS Clinical Genomic Services (NHS CGSs), commissioned by NHS England, deliver a comprehensive clinical genomic and counselling service that directs the diagnosis, risk assessment and lifelong clinical management of patients of all ages and their families who have, or are at risk of having, a rare genetic or genomic condition. As part of the NHS CGS, the patient and their family will access diagnosis, and management relevant to their particular condition, but also receive support and guidance so that they are able to understand their condition, its implications, and their options in relation to reproduction, screening, prevention and clinical management.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 13:43:08 answering member 4044 label Biography information for Andrew Stephenson
tabling member	3960 label Biography information for Henry Smith

1182700

registered interest
date	04/03/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the capacity of radiotherapy services to be able to cope with anticipated future demand created by improved early cancer diagnosis.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	25076
answer	answer is ministerial correction date of answer 12/03/2020 answer text <p>A capacity planning exercise in England, run by NHS England and NHS Improvement, modelled radiotherapy activity levels over a five year period and it is expected that there will be 1 – 2% increase in referral to radiotherapy. In practice this level of growth remains relatively stable and is regularly monitored in conjunction with service providers.</p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 12/03/2020 16:04:38 answering member 4380 label Biography information for Jo Churchill
tabling member	3960 label Biography information for Henry Smith

1549610

registered interest
date	07/12/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what representations his Department has had from the radiotherapy industry during the last 12 months; and how many meetings his Department has had with representatives from that industry in that time period .
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	105334
answer	answer is ministerial correction date of answer 30/01/2023 answer text <p>A search of the Department’s records showed that there had been 34 correspondence cases from the radiotherapy industry, including from charities and parliamentary groups, received within the last 12 months. Ministers within the Department have met with representatives of Radiotherapy UK, along with members of the All Party Parliamentary Group for Radiotherapy, on several occasions within the last 12 months.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 30/01/2023 16:05:08 answering member 4527 label Biography information for Helen Whately
tabling member	3960 label Biography information for Henry Smith

1361394

registered interest
date	19/10/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the suitability of the new NHS England Quality of Life survey for people diagnosed with a less survivable cancer.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	58813
answer	answer is ministerial correction date of answer 27/10/2021 answer text <p>All people with a cancer diagnosis, including those with a less survivable cancer, are invited to complete the Cancer Quality of Life Survey. This is an initiative aimed specifically at supporting long term survivorship. For cancer patients who sadly do not survive for 18 months from diagnosis other approaches to assessing their experience, such as the Cancer Patient Experience Survey, will be more appropriate.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 27/10/2021 13:15:34 answering member 4492 label Biography information for Maria Caulfield
tabling member	3960 label Biography information for Henry Smith

1365995

registered interest
date	03/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people who are immunosuppressed have not been offered a second dose of the covid-19 vaccine; and how many of those people have blood cancer.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	69065
answer	answer is ministerial correction date of answer 02/03/2022 answer text <p>All those with immunosuppression aged 16 years old and over living in the United Kingdom have been offered a second primary dose of COVID-19 vaccine. Immunosuppressed children aged 12 to 15 years old have also now been offered a second primary dose. The offer of first primary doses to immunosuppressed children aged five to 11 years old commenced on 31 January 2022. Vaccination data for those with blood cancer is not held in the format requested.</p><p> </p><p>As of 20 February 2022, data for those formerly regarded as clinically extremely vulnerable, which includes the immunosuppressed and those with blood cancer, shows an uptake rate of over 93.9% for a second primary dose.</p><p><strong> </strong></p> answering member constituency Erewash answering member printed Maggie Throup question first answered 02/03/2022 10:47:06 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

860743

registered interest
date	12/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care what proportion of patients referred to a multidisciplinary diagnostic centre have been (a) suspected of having blood cancer and (b) diagnosed with blood cancer; and if he will make a statement.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	132100
answer	answer is ministerial correction date of answer 19/03/2018 answer text <p>An evaluation is currently being prepared on the work of the multi-disciplinary diagnostic centres, which will include further information on blood cancer patient referral and diagnosis numbers. A final report will be published in December 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/03/2018 15:32:36 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

1365992

registered interest
date	03/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Casirivimab/imdevimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people have been treated with Ronapreve for covid-19 (a) in each week and (b) in each clinical commissioning group area since that treatment became available; and how many of those recipients had blood cancer.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	69062
answer	answer is ministerial correction date of answer 06/12/2021 answer text <p>An interim clinical policy for Ronapreve (casirivimab and imdevimab) was published on 17 September 2021 and updated on 4 November. Since September 2021, over 1,200 patients in England have received this treatment.</p><p>NHS England and NHS Improvement collect information from trusts on usage based on the criteria set out in the policy for treatment of patients hospitalised due to COVID-19. The data collection is not designed to identify the number of such patients who have blood cancer. The information on the number of patients treated in each clinical commissioning group area and in each week is not currently available.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 06/12/2021 17:15:28 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1128942

registered interest
date	03/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when the operational review of the Cancer Drugs Fund will be published.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	259174
answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>An operational review of the Cancer Drugs Fund is currently underway and will be published this year.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/06/2019 16:35:29 answering member 4455 label Biography information for Seema Kennedy
tabling member	3960 label Biography information for Henry Smith

1459977

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, what progress has been made on the assessment of Evusheld for treating immunocompromised patients.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158928
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>Any public announcement on the procurement of therapeutics would be made after an agreement is reached with companies, as this information is commercially sensitive. The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. Any such therapeutic treatment must provide evidence that it is clinically cost-effective, does not contribute to the generation of new variants and demonstrate sufficient efficacy against Omicron and new variants.</p><p>The Therapeutics Clinical Review Panel is providing advice on the most appropriate patient cohorts for new COVID-19 therapeutics, including preventive treatments such as Evusheld. Final clinical policies and eligibility would be determined by the National Health Service and the devolved administrations.</p> answering member constituency Erewash answering member printed Maggie Throup grouped question UIN 158929 159058 question first answered 28/04/2022 08:34:34 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1459978

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, when patients in the UK will have access to Evusheld as a preventative treatment for covid-19.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158929
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>Any public announcement on the procurement of therapeutics would be made after an agreement is reached with companies, as this information is commercially sensitive. The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. Any such therapeutic treatment must provide evidence that it is clinically cost-effective, does not contribute to the generation of new variants and demonstrate sufficient efficacy against Omicron and new variants.</p><p>The Therapeutics Clinical Review Panel is providing advice on the most appropriate patient cohorts for new COVID-19 therapeutics, including preventive treatments such as Evusheld. Final clinical policies and eligibility would be determined by the National Health Service and the devolved administrations.</p> answering member constituency Erewash answering member printed Maggie Throup grouped question UIN 158928 159058 question first answered 28/04/2022 08:34:34 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith